Characteristics of the 21 patients in whom LPD developed
| Patient . | Age, y/sex . | Reason for OLT . | Immunosuppressive regimen . | Acute graft rejection . |
|---|---|---|---|---|
| 1 | 34/F | Primary biliary cirrhosis | Steroids, Aza, ATG (10 days), tacrolimus | Yes |
| 2 | 19/M | Glycogenosis | Steroids, tacrolimus | No |
| 3 | 42/M | Fulminant hepatitis | Steroids, Aza, ATG (14 days), tacrolimus | Yes (OKT3) |
| 4 | 45/M | Hemochromatosis | Steroids, Aza, tacrolimus | Yes |
| 5 | 53/F | HBV + renal chronic rejection | Steroids, Aza, ATG (10 days), tacrolimus | No |
| 6 | 50/F | HBV fulminant hepatitis | Steroids, tacrolimus | Yes |
| 7 | 57/F | HCV | Steroids, Aza, CyA | No |
| 8 | 46/M | HBV + renal chronic rejection | Steroids, Aza, ATG (10 days), tacrolimus | No |
| 9 | 34/F | Amyloid polyneuropathy | Steroids, Aza, ATG 10 days, tacrolimus | No |
| 10 | 29/M | HCV | Steroids, Aza, CyA | Yes |
| 11 | 51/M | HBV | Steroids, tacrolimus | No |
| 12 | 48/M | Alcohol abuse | Steroids, tacrolimus | No |
| 13 | 38/M | HBV | Steroids, anti-CD25, CyA | Yes |
| 14 | 44/F | HBV + HCV | Steroids, Aza, CyA | No |
| 15 | 34/M | HCV + sclerosing cholangitis | Steroids, tacrolimus | No |
| 16 | 42/M | HBV + HDV | Steroids, tacrolimus | Yes (OKT3, then long term) |
| 17 | 54/M | HCV | Steroids, Aza, CyA | No |
| 18 | 55/M | HCV | Steroids, tacrolimus | Yes |
| 19 | 42/M | Alcohol abuse | Steroids, Aza, CyA | No |
| 20 | 51/M | HBV + HDV | Steroids, Aza, CyA | No |
| 21 | 39/M | HBV + HDV | Steroids, Aza, CyA | No |
| Patient . | Age, y/sex . | Reason for OLT . | Immunosuppressive regimen . | Acute graft rejection . |
|---|---|---|---|---|
| 1 | 34/F | Primary biliary cirrhosis | Steroids, Aza, ATG (10 days), tacrolimus | Yes |
| 2 | 19/M | Glycogenosis | Steroids, tacrolimus | No |
| 3 | 42/M | Fulminant hepatitis | Steroids, Aza, ATG (14 days), tacrolimus | Yes (OKT3) |
| 4 | 45/M | Hemochromatosis | Steroids, Aza, tacrolimus | Yes |
| 5 | 53/F | HBV + renal chronic rejection | Steroids, Aza, ATG (10 days), tacrolimus | No |
| 6 | 50/F | HBV fulminant hepatitis | Steroids, tacrolimus | Yes |
| 7 | 57/F | HCV | Steroids, Aza, CyA | No |
| 8 | 46/M | HBV + renal chronic rejection | Steroids, Aza, ATG (10 days), tacrolimus | No |
| 9 | 34/F | Amyloid polyneuropathy | Steroids, Aza, ATG 10 days, tacrolimus | No |
| 10 | 29/M | HCV | Steroids, Aza, CyA | Yes |
| 11 | 51/M | HBV | Steroids, tacrolimus | No |
| 12 | 48/M | Alcohol abuse | Steroids, tacrolimus | No |
| 13 | 38/M | HBV | Steroids, anti-CD25, CyA | Yes |
| 14 | 44/F | HBV + HCV | Steroids, Aza, CyA | No |
| 15 | 34/M | HCV + sclerosing cholangitis | Steroids, tacrolimus | No |
| 16 | 42/M | HBV + HDV | Steroids, tacrolimus | Yes (OKT3, then long term) |
| 17 | 54/M | HCV | Steroids, Aza, CyA | No |
| 18 | 55/M | HCV | Steroids, tacrolimus | Yes |
| 19 | 42/M | Alcohol abuse | Steroids, Aza, CyA | No |
| 20 | 51/M | HBV + HDV | Steroids, Aza, CyA | No |
| 21 | 39/M | HBV + HDV | Steroids, Aza, CyA | No |
In patients 1 to 13, LPD developed in the first year after orthotopic liver transplantation; in patients 14 to 21, LPD developed more than 2 years after OLT.
Aza indicates azathioprine; ATG, antithymocyte globulins; and CyA, cyclosporine.